These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30292625)

  • 1. Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer.
    Watson GA; Deac O; Aslam R; O'Dwyer R; Tierney A; Sukor S; Kennedy J
    Clin Breast Cancer; 2019 Feb; 19(1):e186-e194. PubMed ID: 30292625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
    Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
    Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
    Stearns V; Brufsky AM; Verma S; Cotter MJ; Lu DR; Dequen F; Joy AA
    Clin Breast Cancer; 2018 Dec; 18(6):e1239-e1245. PubMed ID: 30172722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
    Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
    Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
    Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
    Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
    Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
    J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
    Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
    Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
    Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
    Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
    Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
    Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
    Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
    Mukai H; Shimizu C; Masuda N; Ohtani S; Ohno S; Takahashi M; Yamamoto Y; Nishimura R; Sato N; Ohsumi S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Lu DR; Toi M
    Int J Clin Oncol; 2019 Mar; 24(3):274-287. PubMed ID: 30515674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR
    Brufsky A; Mitra D; Davis KL; Nagar SP; McRoy L; Cotter MJ; Stearns V
    Clin Breast Cancer; 2019 Oct; 19(5):317-325.e4. PubMed ID: 31104984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
    Battisti NML; Kingston B; King J; Denton A; Waters S; Sita-Lumsden A; Rehman F; Stavraka C; Kristeleit H; Sawyer E; Houghton D; Davidson N; Howell S; Choy J; Harper P; Roylance R; Fharat R; Mohammed K; Ring A; Johnston S
    Breast Cancer Res Treat; 2019 Apr; 174(3):731-740. PubMed ID: 30656459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
    Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
    Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.
    Seki H; Sakurai T; Maeda Y; Oki N; Aoyama M; Yamaguchi R; Tokuda T; Kaburagi T; Okumura T; Karahashi T; Nakajima K; Higeta K; Shimizu K
    In Vivo; 2019; 33(6):2037-2044. PubMed ID: 31662535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
    Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
    Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
    Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
    Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
    Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
    Ham A; Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
    Breast Cancer Res Treat; 2020 Aug; 183(1):107-116. PubMed ID: 32577940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.